DR. KEITH L DUNCAN, M.D.
Medical Practice at El Camino Real, Burlingame, CA
License number
California G47683
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
2
1783 El Camino Real DEPT PATHOLOGY, Burlingame, CA 94010
PO Box 281560, San Francisco, CA 94128
PO Box 281560, San Francisco, CA 94128
Phone
(650) 696-5611
(650) 616-2948
(650) 616-2948
Personal information
See more information about KEITH L DUNCAN at radaris.comName
Address
Phone
4392 Elm Ave, Long Beach, CA 90807
3301 Coulterville Dr, Modesto, CA 95354
3301 Coulterville Dr #C, Modesto, CA 95354
3470 French Ave, W Sacramento, CA 95691
3975 Loma Alta Dr, San Diego, CA 92115
Professional information
Senior Inside Sales Representative At Informatica Corporation
Position:
Business Development Manager at Realization
Location:
San Francisco Bay Area
Industry:
Computer Software
Work:
Realization
since Feb 2010
-
Business Development Manager
Informatica
Jan 2008 - Apr 2009
-
Senior Inside Sales Executive
Washington Mutual Home Loans
Jan 2003 - Jan 2008
-
Senior Residential Loan Consultant
Silicon Graphics Corporation
Jan 1999 - Jul 2002
-
Channel Marketing/Development Manager
Education:
University of California, Davis 1979 - 1984
BS, Managerial Economics
BS, Managerial Economics
Business Development Manager At Realization Technologies
Position:
Business Development Manager at Realization Technologies
Location:
San Francisco Bay Area
Industry:
Mechanical or Industrial Engineering
Work:
Realization Technologies
-
Business Development Manager
Dr. Keith L Duncan, Burlingame CA - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
Peninsula Pathologists Medical Group
1501 Trousdale Dr, Burlingame 94010
(650) 696-5511 (Phone)
Peninsula Pathologists Med Grp
1501 Trousdale Dr, Burlingame 94010
(650) 696-5511 (Phone)
1501 Trousdale Dr, Burlingame 94010
(650) 696-5511 (Phone)
Peninsula Pathologists Med Grp
1501 Trousdale Dr, Burlingame 94010
(650) 696-5511 (Phone)
Certifications:
Anatomic & Clinical Pathology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Southern California / Keck School of Medicine
Graduated: 1981
Los Angeles Co Med Ctr
Uc-San Francisco
University of Southern California / Keck School of Medicine
Graduated: 1981
Los Angeles Co Med Ctr
Uc-San Francisco
Research Biochemist At University Of California
Position:
Research Biochemist at University of California
Location:
San Francisco Bay Area
Industry:
Medical Devices
Work:
University of California
-
Research Biochemist
Keith L Duncan, Burlingame CA
Specialties:
Pathologist
Address:
1783 El Camino Real, Burlingame, CA 94010
Education:
University of Southern California, Keck School of Medicine - Doctor of Medicine
UCSF Medical Center - Residency - Pathology
UCSF Medical Center - Residency - Pathology
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Methods To Increase Reverse Cholesterol Transport In The Retinal Pigment Epithelium (Rpe) And Bruch's Membrane (Bm)
US Patent:
7470659, Dec 30, 2008
Filed:
Mar 5, 2004
Appl. No.:
10/794198
Inventors:
Daniel M. Schwartz - San Francisco CA, US
Keith G. Duncan - San Francisco CA, US
Kathy R. Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
Keith G. Duncan - San Francisco CA, US
Kathy R. Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 38/02, A61K 38/17, A61K 31/685
US Classification:
514 2, 514 12, 514 13, 514 21, 514 78
Abstract:
The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
Treatments For Age-Related Macular Degeneration (Amd)
US Patent:
2003022, Dec 11, 2003
Filed:
May 2, 2003
Appl. No.:
10/428551
Inventors:
Daniel Schwartz - San Francisco CA, US
Keith Duncan - San Francisco CA, US
Kathy Bailey - San Francisco CA, US
John Kane - Hillsborough CA, US
Brian Ishida - Walnut Creek CA, US
Keith Duncan - San Francisco CA, US
Kathy Bailey - San Francisco CA, US
John Kane - Hillsborough CA, US
Brian Ishida - Walnut Creek CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K031/58, A61K031/56, A61K031/203, A61K031/198
US Classification:
514/177000, 514/559000, 514/567000, 514/172000
Abstract:
The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.
Treatment For Dark Adaptation
US Patent:
2010004, Feb 25, 2010
Filed:
Oct 6, 2008
Appl. No.:
12/245944
Inventors:
Daniel M. Schwartz - San Francisco CA, US
Keith G. Duncan - San Francisco CA, US
Kathy R. Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
Keith G. Duncan - San Francisco CA, US
Kathy R. Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
International Classification:
A61K 9/127, A61K 38/17, A61P 27/02
US Classification:
424450, 514 12
Abstract:
The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
Treatment For Age-Related Macular Degeneration (Amd)
US Patent:
2003016, Aug 28, 2003
Filed:
Dec 6, 2002
Appl. No.:
10/313641
Inventors:
Daniel Schwartz - San Francisco CA, US
Keith Duncan - San Francisco CA, US
Kathy Bailey - San Francisco CA, US
John Kane - San Francisco CA, US
Brian Ishida - Walnut Creek CA, US
Keith Duncan - San Francisco CA, US
Kathy Bailey - San Francisco CA, US
John Kane - San Francisco CA, US
Brian Ishida - Walnut Creek CA, US
International Classification:
A61K031/58, A61K031/56, A61K031/381, A61K031/203, A61K031/192
US Classification:
514/172000, 514/178000, 514/567000, 514/559000, 514/438000, 514/570000
Abstract:
The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.
Biodegradable Peg Based Polymer Formulations In Ocular Applications
US Patent:
2003022, Dec 4, 2003
Filed:
Apr 10, 2003
Appl. No.:
10/410860
Inventors:
Daniel Schwartz - San Francisco CA, US
Keith Duncan - San Francisco CA, US
Jay Stewart - Fort Lauderdale FL, US
Keith Duncan - San Francisco CA, US
Jay Stewart - Fort Lauderdale FL, US
International Classification:
A61K031/765
US Classification:
424/078380
Abstract:
The present invention relates to methods and pharmaceutical compositions involving the use of bioerodible (biodegradable) polymers to address fundamental needs in ocular surgery including sealants and sealing methods, barriers to cellular adhesion and proliferation, and mechanical barriers. In a particular embodiment, the present invention is also directed to the treatment of intraocular hypotony in an eye by limiting the flow of aqueous from the eye. In a preferred embodiment, application of a polymer, such as to the angle of the eye, limits the flow, thereby increasing the intraocular pressure.